Literature DB >> 11718874

Neuroprotective peptide drug delivery and development: potential new therapeutics.

I Gozes1.   

Abstract

Alzheimer's disease and related neurodegenerative disorders are prevalent among the elderly and might be considered as the plague of the 21st century. It is thus imperative to find cures for these conditions. The use of nerve growth factor proteins as neuroprotective therapeutics is limited by their hindered mobility through the blood-brain barrier. Peptides provide an attractive alternative. However, do peptide derivatives retain the activity of the entire protein? Are they stable? Would peptides cross the blood-brain barrier and what are the potential side effects? Examples are put forth to strengthen our opinion that peptides are important candidates for future drug development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11718874     DOI: 10.1016/s0166-2236(00)01931-7

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  19 in total

1.  Alzheimer's disease: my point of view.

Authors:  I Gozes
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 2.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

3.  Exosomes as drug delivery vehicles for Parkinson's disease therapy.

Authors:  Matthew J Haney; Natalia L Klyachko; Yuling Zhao; Richa Gupta; Evgeniya G Plotnikova; Zhijian He; Tejash Patel; Aleksandr Piroyan; Marina Sokolsky; Alexander V Kabanov; Elena V Batrakova
Journal:  J Control Release       Date:  2015-03-31       Impact factor: 9.776

4.  Techniques for neuropeptide determination.

Authors:  Mats Sandberg; Stephen G Weber
Journal:  Trends Analyt Chem       Date:  2003-09       Impact factor: 12.296

Review 5.  Nanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandi.

Authors:  Vladimir N Uversky; Alexander V Kabanov; Yuri L Lyubchenko
Journal:  J Proteome Res       Date:  2006-10       Impact factor: 4.466

6.  Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells.

Authors:  Matthew J Haney; Yuling Zhao; Shu Li; Sheila M Higginbotham; Stephanie L Booth; Huai-Yun Han; Joseph A Vetro; R Lee Mosley; Alexander V Kabanov; Howard E Gendelman; Elena V Batrakova
Journal:  Nanomedicine (Lond)       Date:  2011-03-31       Impact factor: 5.307

7.  A macrophage-nanozyme delivery system for Parkinson's disease.

Authors:  Elena V Batrakova; Shu Li; Ashley D Reynolds; R Lee Mosley; Tatiana K Bronich; Alexander V Kabanov; Howard E Gendelman
Journal:  Bioconjug Chem       Date:  2007-08-31       Impact factor: 4.774

8.  Brain injury-dependent expression of activity-dependent neuroprotective protein.

Authors:  Roy Zaltzman; Alexander Alexandrovich; Sara M Beni; Victoria Trembovler; Esther Shohami; Illana Gozes
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 9.  Unlocking the secrets to protein-protein interface drug targets using structural mass spectrometry techniques.

Authors:  Angela Dailing; Alessandra Luchini; Lance Liotta
Journal:  Expert Rev Proteomics       Date:  2015-09-01       Impact factor: 3.940

Review 10.  Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin.

Authors:  Tomohiro Chiba; Ikuo Nishimoto; Sadakazu Aiso; Masaaki Matsuoka
Journal:  Mol Neurobiol       Date:  2007-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.